Biomarkers and Personalized Approach to Cancer Group (BioPAC)
2022 Activity indicators
- 4 public competitive projects led - ISCIII, MICINN
- 2 competitive private projects
- 8 competitive HR contracts
- 4 publications.
- IF: 68.01
- D1 publications: 3 (75 %).
- Q1 publications: 4 (100 %).
- Evaluator in public entities: 2 PI
- Member of editorial committees: 1 PI.
- 3 hosted visitors and 2 months stay:
- ULM University (Germany)
- University College London (United Kingdom)
- IDIS - Hosp. Clínico Univ. S. de Compostela (Spain)
Milestones
-
Alonso-Nocelo M., Ruiz-Cañas L.*....Cano A., and Sainz B. Jr. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Gut, 2022; 72(2):345-359. FI:31.840 Q1/D1
-
Frank K.J., ...Sainz B. Jr., Bernards R., Algül H., Lesina M., Mainardi S. Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. Cell Reports Medicine, 2022; 3(11):100815. FI:16.988 Q1/D1
-
CO-IP del Grupo CIBERONC CB16/12/00446 que dirige el Dr. Alfredo Carrato.
-
Éxito en concesión ayudas competitivas de RRHH; Juan de la Cierva Formación 2020 (FJC2020-044220-I), Ayudas de la CAM para Técnicos de laboratorio (PEJ-2021-TL/BMD-22441) y un contrato del programa "Yo Investigo".
-
Participación como miembros del Equipo del Proyecto "Selectively eliminating cancer stem cells through inhibition of mitochondrial respiration using metal-based small molecules", La Caixa research Consolidate 2021 (CC21-20122).
Bibliometrics
Articles | Accum. FI | Mean FI | Articles Q1 or Q2 | % in Q1 or Q2 | Articles D1 | % in D1 | |
---|---|---|---|---|---|---|---|
2018 | 7 | 44,10 | 7,35 | 6 | 86 | 3 | 43 |
2019 | 6 | 51,59 | 8,60 | 6 | 100 | 3 | 50 |
2020 | 11 | 70,19 | 6,38 | 11 | 100 | 3 | 27 |
2021 | 9 | 96,74 | 10,75 | 9 | 100 | 2 | 22 |
2022 | 4 | 68,014 | 17,00 | 4 | 100 | 3 | 75 |
37 | 330,63 | 10,02 | 36 | 97 | 14 | 38 |
* Only original articles, editorials, guideline and reviews